

BIOSPECIFICS TECHNOLOGIES CORP

Form 4

August 19, 2008

FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

 1. Name and Address of Reporting Person *
 Vogel Jeffrey Kenneth

 2. Issuer Name and Ticker or Trading Symbol
 BIOSPECIFICS TECHNOLOGIES
 CORP [BSTC.OB]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

1 MEADOW DRIVE

(Street)

 3. Date of Earliest Transaction
 (Month/Day/Year)
 07/20/2007

 _____ Director _____ 10% Owner
 _____ Officer (give title below) ☒ Other (specify below)
 5% Owner

LAWRENCE, NY 11559

(City) (State) (Zip)

 4. If Amendment, Date Original
 Filed(Month/Day/Year)

 6. Individual or Joint/Group Filing(Check Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock	07/20/2007		P	1,000 A \$ 4.6	497,041	I	See Footnote (1)
Common Stock	07/26/2007		P	500 A \$ 4.6	497,541	I	See Footnote (1)
Common Stock	07/26/2007		P	500 A \$ 4.65	498,041	I	See Footnote (1)
Common Stock	07/27/2007		P	500 A \$ 4.65	498,541	I	See Footnote

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

								<u>(1)</u>
Common Stock	07/31/2007	P	500	A	\$ 4.65	499,041	I	See Footnote <u>(1)</u>
Common Stock	08/03/2007	P	500	A	\$ 4.72	499,541	I	See Footnote <u>(1)</u>
Common Stock	08/06/2007	P	500	A	\$ 4.75	500,041	I	See Footnote <u>(1)</u>
Common Stock	08/07/2007	P	2,000	A	\$ 4.95	502,041	I	See Footnote <u>(1)</u>
Common Stock	08/08/2007	P	1,000	A	\$ 5.1	503,041	I	See Footnote <u>(1)</u>
Common Stock	03/19/2008	P	500	A	\$ 10	503,541	I	See Footnote <u>(1)</u>
Common Stock	03/19/2008	P	1,500	A	\$ 10.1	505,041	I	See Footnote <u>(1)</u>
Common Stock	03/20/2008	P	500	A	\$ 10	505,541	I	See Footnote <u>(1)</u>
Common Stock	05/19/2008	P	350	A	\$ 10.25	505,891	I	See Footnote <u>(1)</u>
Common Stock	05/21/2008	P	140	A	\$ 12	506,031	I	See Footnote <u>(1)</u>
Common Stock	05/22/2008	P	1,500	A	\$ 12	507,531	I	See Footnote <u>(1)</u>
Common Stock	05/30/2008	P	700	A	\$ 12	508,231	I	See Footnote <u>(1)</u>
Common Stock	06/03/2008	P	1,200	A	\$ 11.25	509,431	I	See Footnote <u>(1)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474
(9-02)

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 3)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
Vogel Jeffrey Kenneth 1 MEADOW DRIVE LAWRENCE, NY 11559	5% Owner

Signatures

/s/ JEFFREY K.
VOGEL 08/18/2008

__Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes (i) 214,119 common shares owned by Jeffrey K. Vogel and (ii) 295,312 common shares held by Bio Partners LP (Jeffrey Vogel is the sole shareholder and President of Bio Management Inc., the sole general partner of Bio Partners L.P.)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.